Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 3

Management of tinea capitis in childhood

Authors Bennassar A, Grimalt R

Published 14 July 2010 Volume 2010:3 Pages 89—98

DOI https://doi.org/10.2147/CCID.S7992

Review by Single anonymous peer review

Peer reviewer comments 2

Download Article [PDF] 

Antoni Bennassar, Ramon Grimalt

Dept of Dermatology, Hospital Clinic, University of Barcelona, Barcelona, Spain

Abstract: Tinea capitis (TC) is a common dermatophyte infection affecting primarily ­prepubertal children. The causative pathogens belong to only two genera: Trichophyton and Microsporum. Although there is a great local variation in the epidemiology of TC worldwide, T. tonsurans is currently the most common cause of TC with M. canis second. Even though there is an emerging number of anthropophilic scalp infections, M. canis remains the predominant causative organism in many countries of the Mediterranean basin, the most important dermatophyte carriers being stray cats and dogs as well as pet puppies, kittens and rabbits. TC always requires systemic treatment because topical antifungal agents do not penetrate down to the deepest part of the hair follicle. Since the late 1950s, griseofulvin has been the gold standard for systemic therapy of TC. It is active against dermatophytes and has a long-term safety profile. The main disadvantage of griseofulvin is the long duration of treatment required which may lead to reduced compliance. The newer oral antifungal agents including terbinafine, itraconazole, ketokonazole, and fluconazole appear to have efficacy rates and potential adverse effects similar to those of griseofulvin in children with TC caused by Trichophyton species, while requiring a much shorter duration of treatment. They may, however, be more expensive.

Keywords: tinea capitis, children, fungal infection, greseofulvin, terbinafine, itraconazole, fluconazole, treatment, pediatric infection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]